Published in Oncologist on May 01, 2008
The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas (2010) 2.84
The role of Cdk5 in neuroendocrine thyroid cancer. Cancer Cell (2013) 1.30
New developments in the diagnosis and treatment of thyroid cancer. CA Cancer J Clin (2013) 1.16
A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma. Oncologist (2011) 1.05
Tautomycetin and tautomycin suppress the growth of medullary thyroid cancer cells via inhibition of glycogen synthase kinase-3beta. Mol Cancer Ther (2009) 1.05
Current understanding and management of medullary thyroid cancer. Oncologist (2013) 0.99
Suberoyl bishydroxamic acid activates notch1 signaling and suppresses tumor progression in an animal model of medullary thyroid carcinoma. Ann Surg Oncol (2008) 0.98
Predominant RET Germline Mutations in Exons 10, 11, and 16 in Iranian Patients with Hereditary Medullary Thyroid Carcinoma. J Thyroid Res (2011) 0.95
p53 suppresses carcinoma progression by inhibiting mTOR pathway activation. Oncogene (2014) 0.94
Inhibition of growth in medullary thyroid cancer cells with histone deacetylase inhibitors and lithium chloride. J Surg Res (2008) 0.94
New targeted therapies for thyroid cancer. Curr Genomics (2011) 0.93
Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study. J Cell Mol Med (2012) 0.92
Expression of the active Notch1 decreases MTC tumor growth in vivo. J Surg Res (2011) 0.91
Utility of a PI3K/mTOR inhibitor (NVP-BEZ235) for thyroid cancer therapy. PLoS One (2012) 0.90
Notch in the development of thyroid C-cells and the treatment of medullary thyroid cancer. Am J Transl Res (2010) 0.85
Signaling pathways as specific pharmacologic targets for neuroendocrine tumor therapy: RET, PI3K, MEK, growth factors, and Notch. Neuroendocrinology (2012) 0.85
Multi-targeted approach in the treatment of thyroid cancer. Minerva Chir (2010) 0.85
RET gene abnormalities and thyroid disease: who should be screened and when. J Clin Res Pediatr Endocrinol (2013) 0.85
Peptide receptor radionuclide therapy of treatment-refractory metastatic thyroid cancer using (90)Yttrium and (177)Lutetium labeled somatostatin analogs: toxicity, response and survival analysis. Am J Nucl Med Mol Imaging (2013) 0.85
Octreotide-functionalized and resveratrol-loaded unimolecular micelles for targeted neuroendocrine cancer therapy. Nanoscale (2013) 0.84
Molecular profiling of thyroid cancer subtypes using large-scale text mining. BMC Med Genomics (2014) 0.83
Hereditary medullary thyroid cancer: age-appropriate thyroidectomy improves disease-free survival. Ann Surg Oncol (2012) 0.83
KE108-conjugated unimolecular micelles loaded with a novel HDAC inhibitor thailandepsin-A for targeted neuroendocrine cancer therapy. Biomaterials (2016) 0.82
Hedgehog signaling in human medullary thyroid carcinoma: a novel signaling pathway. Thyroid (2013) 0.81
MK-2206 causes growth suppression and reduces neuroendocrine tumor marker production in medullary thyroid cancer through Akt inhibition. Ann Surg Oncol (2013) 0.81
Medullary thyroid carcinoma: targeted therapies and future directions. J Oncol (2009) 0.81
Thiocoraline alters neuroendocrine phenotype and activates the Notch pathway in MTC-TT cell line. Cancer Med (2013) 0.80
Xanthohumol inhibits the neuroendocrine transcription factor achaete-scute complex-like 1, suppresses proliferation, and induces phosphorylated ERK1/2 in medullary thyroid cancer. Am J Surg (2010) 0.79
From preclinical development to clinical application: Kit formulation for radiolabelling the minigastrin analogue CP04 with In-111 for a first-in-human clinical trial. Eur J Pharm Sci (2016) 0.78
A role for radiotherapy in the management of advanced medullary thyroid carcinoma: the mayo clinic experience. Rare Tumors (2013) 0.78
Oncogenetics service and the Brazilian public health system: the experience of a reference Cancer Hospital. Genet Mol Biol (2016) 0.77
Reduced USP39 expression inhibits malignant proliferation of medullary thyroid carcinoma in vitro. World J Surg Oncol (2015) 0.77
Pregnancy and thyroid cancer: ultrasound study of foetal thyroid. Acta Otorhinolaryngol Ital (2009) 0.77
Glucagon-Like Peptide-1 Receptor Imaging with [Lys (40) (Ahx-HYNIC- (99 m) Tc/EDDA)NH 2 ]-Exendin-4 for the Diagnosis of Recurrence or Dissemination of Medullary Thyroid Cancer: A Preliminary Report. Int J Endocrinol (2013) 0.76
Nuclear Medicine in Thyroid Diseases in Pediatric and Adolescent Patients. Mol Imaging Radionucl Ther (2015) 0.75
A Brief Review on The Molecular Basis of Medullary Tyroid Carcinoma. Cell J (2016) 0.75
Oncocytic Variant of Medullary Thyroid Carcinoma: A Rare Case of Sporadic Multifocal and Bilateral RET Wild-Type Neoplasm with Revision of the Literature. Rare Tumors (2016) 0.75
Lentivirus-mediated silencing of MPHOSPH8 inhibits MTC proliferation and enhances apoptosis. Oncol Lett (2016) 0.75
Differences in the transcriptome of medullary thyroid cancer regarding the status and type of RET gene mutations. Sci Rep (2017) 0.75
Medullary thyroid carcinoma: The third most common thyroid cancer reviewed. Oncol Lett (2010) 0.75
Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma. Oncology (2016) 0.75
Recurrent spinal metastasis of a sporadic medullary carcinoma of the thyroid after radiation therapy: a case report and review of the literature. Clin Case Rep (2015) 0.75
Pediatric Medullary Thyroid Carcinoma. J Pediatr Oncol (2016) 0.75
Calcitonin-Secreting Neuroendocrine Carcinoma of Larynx with Metastasis to Thyroid. Case Rep Endocrinol (2015) 0.75
Nodular Graves' disease with medullary thyroid cancer. Indian J Nucl Med (2015) 0.75
AB3-Loaded and Tumor-Targeted Unimolecular Micelles for Medullary Thyroid Cancer Treatment. J Mater Chem B Mater Biol Med (2016) 0.75
Medullary Thyroid Cancer: Clinical Characteristics and New Insights into Therapeutic Strategies Targeting Tyrosine Kinases. Mol Diagn Ther (2017) 0.75
National Trends in the Surgical Treatment of Non-advanced Medullary Thyroid Cancer (MTC): An Evaluation of Adherence with the 2009 American Thyroid Association Guidelines. World J Surg (2016) 0.75
A large Chinese pedigree of multiple endocrine neoplasia type 2A with a novel C634Y/D707E germline mutation in RET exon 11. Oncol Lett (2017) 0.75
Carcinoid tumors. Oncologist (2008) 2.86
Is there still a glass ceiling for women in academic surgery? Ann Surg (2011) 2.33
Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab (2007) 2.26
Using body mass index to predict optimal thyroid dosing after thyroidectomy. J Am Coll Surg (2013) 2.10
Overexpression of the NOTCH1 intracellular domain inhibits cell proliferation and alters the neuroendocrine phenotype of medullary thyroid cancer cells. J Biol Chem (2006) 2.05
Pheochromocytoma: current approaches and future directions. Oncologist (2008) 2.05
Incidence and localization of ectopic parathyroid adenomas in previously unexplored patients. World J Surg (2013) 1.96
Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells. Oncologist (2007) 1.96
Inactivation of glycogen synthase kinase-3beta, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells. Mol Cancer Ther (2007) 1.85
Tumor suppressor role of Notch-1 signaling in neuroendocrine tumors. Oncologist (2007) 1.78
Follicular variant of papillary thyroid carcinoma is a unique clinical entity: a population-based study of 10,740 cases. Thyroid (2013) 1.77
Raf-1 activation suppresses neuroendocrine marker and hormone levels in human gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol (2003) 1.76
Is Hashimoto's thyroiditis a risk factor for papillary thyroid cancer? J Surg Res (2007) 1.75
A rising ioPTH level immediately after parathyroid resection: are additional hyperfunctioning glands always present? An application of the Wisconsin Criteria. Ann Surg (2010) 1.71
Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas (2013) 1.65
Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases. Ann Surg (2011) 1.64
Conservation of the Notch1 signaling pathway in gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol (2005) 1.59
Isolated adrenal mass in patients with a history of cancer: remember pheochromocytoma. Ann Surg Oncol (2007) 1.56
Remnant uptake as a postoperative oncologic quality indicator. Thyroid (2013) 1.56
The utility of frozen section evaluation for follicular thyroid lesions. Ann Surg Oncol (2004) 1.53
ZM336372, a Raf-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumor cells. Mol Cancer Ther (2005) 1.53
25-hydroxyvitamin D status does not affect intraoperative parathyroid hormone dynamics in patients with primary hyperparathyroidism. Ann Surg Oncol (2010) 1.50
Can thallium-pertechnetate subtraction scanning play a role in the preoperative imaging for minimally invasive parathyroidectomy? Clin Nucl Med (2004) 1.47
Radioguided parathyroidectomy in patients with familial hyperparathyroidism. Ann Surg Oncol (2006) 1.46
Thyroidectomy decreases snoring and sleep apnea symptoms. Thyroid (2012) 1.46
Carcinoid tumors. Surg Oncol Clin N Am (2006) 1.45
Pancreatic endocrine tumors. J Surg Res (2004) 1.42
Tertiary hyperparathyroidism: is less than a subtotal resection ever appropriate? A study of long-term outcomes. Surgery (2009) 1.42
The necessity and reliability of intraoperative parathyroid hormone (PTH) testing in patients with mild hyperparathyroidism and PTH levels in the normal range. World J Surg (2011) 1.42
Clinical efficacy of fine-needle aspiration biopsy of thyroid nodules in males. J Surg Res (2009) 1.42
All thyroid ultrasound evaluations are not equal: sonographers specialized in thyroid cancer correctly label clinical N0 disease in well differentiated thyroid cancer. Ann Surg Oncol (2014) 1.41
How Well Does Renal Transplantation Cure Hyperparathyroidism? Ann Surg (2015) 1.40
Valproic acid activates Notch1 signaling and induces apoptosis in medullary thyroid cancer cells. Ann Surg (2008) 1.39
Regulation of neuroendocrine differentiation in gastrointestinal carcinoid tumor cells by notch signaling. J Clin Endocrinol Metab (2005) 1.39
The role of human achaete-scute homolog-1 in medullary thyroid cancer cells. Surgery (2003) 1.37
Apoptosis-mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY294002. Surgery (2006) 1.34
Secondary and tertiary hyperparathyroidism, state of the art surgical management. Surg Clin North Am (2009) 1.34
Treatment of advanced carcinoid tumors. Curr Opin Oncol (2006) 1.32
Higher serum TSH in thyroid cancer patients occurs independent of age and correlates with extrathyroidal extension. Clin Endocrinol (Oxf) (2008) 1.31
Long-term follow-up of patients with tertiary hyperparathyroidism treated by resection of a single or double adenoma. Ann Surg (2002) 1.30
The role of Cdk5 in neuroendocrine thyroid cancer. Cancer Cell (2013) 1.30
Hairy Enhancer of Split-1 (HES-1), a Notch1 effector, inhibits the growth of carcinoid tumor cells. Surgery (2005) 1.28
Surgery for primary hyperparathyroidism: what is the best approach? Ann Surg (2002) 1.26
Notch 1 signaling is active in ovarian cancer. Gynecol Oncol (2010) 1.23
Radioguided parathyroidectomy via VATS combined with intraoperative parathyroid hormone testing: the surgical approach of choice for patients with mediastinal parathyroid adenomas? J Bone Miner Res (2002) 1.22
Metastatic neuroendocrine hepatic tumors: resection improves survival. Arch Surg (2006) 1.22
Suberoyl bis-hydroxamic acid activates Notch-1 signaling and induces apoptosis in medullary thyroid carcinoma cells. Oncologist (2008) 1.21
What is the clinical significance of an elevated parathyroid hormone level after curative surgery for primary hyperparathyroidism? Ann Surg (2009) 1.20
Suberoyl bishydroxamic acid inhibits cellular proliferation by inducing cell cycle arrest in carcinoid cancer cells. J Gastrointest Surg (2007) 1.19
Gastrointestinal carcinoid tumors: factors that predict outcome. World J Surg (2004) 1.18
The Raf-1 pathway: a molecular target for treatment of select neuroendocrine tumors? Anticancer Drugs (2006) 1.17
Accuracy of fine-needle aspiration biopsy for predicting neoplasm or carcinoma in thyroid nodules 4 cm or larger. Arch Surg (2009) 1.17
Is minimally invasive parathyroidectomy associated with greater recurrence compared to bilateral exploration? Analysis of more than 1,000 cases. Surgery (2012) 1.17
New developments in the diagnosis and treatment of thyroid cancer. CA Cancer J Clin (2013) 1.16
Identification and validation of Notch pathway activating compounds through a novel high-throughput screening method. Cancer (2010) 1.15
Medical student operative experience correlates with a match to a categorical surgical program. Am J Surg (2003) 1.15
Total thyroidectomy: a safe and effective treatment for Graves' disease. J Surg Res (2011) 1.15
Impact of lymph node ratio on survival in papillary thyroid cancer. Ann Surg Oncol (2012) 1.14
Medullary thyroid cancer: the functions of raf-1 and human achaete-scute homologue-1. Thyroid (2005) 1.14
Postoperative parathyroid hormone testing decreases symptomatic hypocalcemia and associated emergency room visits after total thyroidectomy. Surgery (2010) 1.14
Contralateral papillary thyroid cancer: does size matter? Am J Surg (2009) 1.14
Radioguided parathyroidectomy in patients with secondary and tertiary hyperparathyroidism. Surgery (2003) 1.12
Why do students choose careers in surgery? J Surg Res (2004) 1.12
MicroRNA profiling of benign and malignant pheochromocytomas identifies novel diagnostic and therapeutic targets. Endocr Relat Cancer (2010) 1.11
Expression of epithelial-mesenchymal transition regulators SNAI2 and TWIST1 in thyroid carcinomas. Mod Pathol (2012) 1.10
Parathyroid hormone deficiency after total thyroidectomy: incidence and time. J Surg Res (2010) 1.10
Calciphylaxis in the absence of end-stage renal disease. Endocr Pract (2006) 1.09
New trends in parathyroid surgery. Curr Probl Surg (2010) 1.09
Lithium ions: a novel treatment for pheochromocytomas and paragangliomas. Surgery (2007) 1.09
The HDAC inhibitor trichostatin A inhibits growth of small cell lung cancer cells. J Surg Res (2007) 1.08
Histone deacetylase inhibitors upregulate Notch-1 and inhibit growth in pheochromocytoma cells. Surgery (2008) 1.08
In patients with thyroid cancer of follicular cell origin, a family history of nonmedullary thyroid cancer in one first-degree relative is associated with more aggressive disease. Thyroid (2011) 1.08
Creation of a "Wisconsin index" nomogram to predict the likelihood of additional hyperfunctioning parathyroid glands during parathyroidectomy. Ann Surg (2013) 1.07
Novel targets for the treatment and palliation of gastrointestinal neuroendocrine tumors. Curr Opin Investig Drugs (2008) 1.06
In-vivo activation of Raf-1 inhibits tumor growth and development in a xenograft model of human medullary thyroid cancer. Anticancer Drugs (2006) 1.06
Radioguided parathyroidectomy for recurrent hyperparathyroidism caused by forearm graft hyperplasia. J Bone Miner Res (2003) 1.06
Older age and larger tumor size predict malignancy in hürthle cell neoplasms of the thyroid. Ann Surg Oncol (2008) 1.06
A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma. Oncologist (2011) 1.05
Tautomycetin and tautomycin suppress the growth of medullary thyroid cancer cells via inhibition of glycogen synthase kinase-3beta. Mol Cancer Ther (2009) 1.05
Thyroid hormone replacement after thyroid lobectomy. Surgery (2009) 1.05
Palliation of advanced thyroid malignancies. Surg Oncol (2007) 1.05
Down-regulation of Notch1 signaling inhibits tumor growth in human hepatocellular carcinoma. Am J Transl Res (2009) 1.04
Preventing postoperative hypocalcemia in patients with Graves disease: a prospective study. Ann Surg Oncol (2014) 1.04
Mitogen-activated protein kinases and chemoresistance in pancreatic cancer cells. J Surg Res (2006) 1.04